Bengt von Mentzer (PhD, CEO) is the original founder of Pharmnovo. His main interest is GPCR functionality and fatty acid metabolism. He has been employed in the departments of Physiology, Bioscience, Pharmacology and Molecular Pharmacology at AstraZeneca. For the last 10 years he has worked as a principal scientist and group leader and has inspired and sponsored new thinking in GI neuropeptide research.


David Kendall (CSO) joined PharmNovo in 2009. Until August 2015, he was  Professor of Pharmacology and former Head of Biomedical Sciences at the University of Nottingham Medical School. He is a Pharmacy graduate with a PhD in Neuropharmacology and worked as an industrial  pharmacologist  before returning to academic research in the Universities of Texas and Leicester. He has an international reputation in GPCR research with particular emphasis on the endocannabinoid signalling system and pain.


Urban Fagerholm picture Urban Fagerholm is associated Professor and pharmacokineticist and stated Prosilico focuses on human and animal ADMET-predictions using new, unique algorithms and in-silico models. Their validated, context-based models (more than 50, including many exclusive) clearly outperform state-of-the-art in-vitro and animal in-vivo methods both regarding quality, range, speed and overview. Prosilicos’ services include advice, early decision-support, compound profiling, risk assessment, platform customization and in/out-licensing evaluation.


Andrew Russo is Professor of Molecular Physiology and Biophysics and Director of the Biosciences Program at the University of Iowa. Dr. Russo has served on NIH and private grant review panels, committees for the Society for Neuroscience and American Physiological Society, and has received several teaching awards. The primary focus of Dr. Russo’s research is to understand the molecular basis of migrane.


 helyes-zs-2016  ZsuZsanna Helyes is professor in Pharmacology at the University of Pecs work in the fields of pain and inflammation and has great expertise in a variety of experimental models with special emphasis on in vivo studies. She also started PharmInVivo and today lead the company which is a spin-out company based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty & Szentagothai Research Center of the University of Pécs. The team focuses on animal models of chronic diseases and has a complete repertoire of nociceptive tests in both rats and mice.